Filing Details

Accession Number:
0001209191-14-067908
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-11-12 12:03:44
Reporting Period:
2014-11-12
Filing Date:
2014-11-12
Accepted Time:
2014-11-12 12:03:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1512762 Coherus Biosciences Inc. CHRS Biological Products, (No Disgnostic Substances) (2836) 273615821
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1245624 James Healy C/o Coherus Biosciences, Inc.
201 Redwood Shores Parkway, Suite 200
Redwood City CA 94065
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2014-11-12 47 $0.00 47 No 4 C Direct
Common Stock, $0.0001 Par Value Acquisiton 2014-11-12 1,846,890 $0.00 1,981,863 No 4 C Indirect See Footnote
Common Stock, $0.0001 Par Value Acquisiton 2014-11-12 149,970 $0.00 2,131,833 No 4 C Indirect See Footnote
Common Stock, $0.0001 Par Value Acquisiton 2014-11-12 425,926 $13.50 2,557,759 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2014-11-12 47 $0.00 47 $0.00
Common Stock Series B Preferred Stock Disposition 2014-11-12 1,846,890 $0.00 1,846,890 $0.00
Common Stock Series C Preferred Stock Disposition 2014-11-12 149,970 $0.00 149,970 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis upon the closing of Issuer's initial public offering.
  2. The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.
  3. Sofinnova Venture Partners VII, L.P. purchased an additional 425,926 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share.
  4. The Series B Preferred Stock and Series C Preferred Stock have no expiration date.